Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage

  • Navarro-Oviedo, Manuel
  • Muñoz, Roberto
  • Zandio, Beatriz
  • Marta-Enguita, Juan
  • Bonaterra-Pastra, Anna
  • Rodríguez, José Antonio
  • Roncal Mancho, Carmen
  • Páramo, José A.
  • Toledo, Estefanía
  • Montaner, Joan
  • Hernández-Guillamon, Mar
  • Orbe, Josune
Matrix metalloproteinases (MMPs) are proteolytic zinc-endopeptidases regulated by tissue Inhibitors of matrix metalloproteinases (TIMPs). We evaluated the potential of MMPs and TIMPs as clinical tools for Intracranial Haemorrhage (ICH). Spontaneous non‐traumatic ICH patients were recruited from two hospitals: Complejo Hospitalario de Navarra (CHN = 29) and Vall d´Hebron (VdH = 76). Plasmatic levels of MMP-1, −2, −7, −9, −10 and TIMP-1 and their relationship with clinical, radiological and functional variables were evaluated. We further studied the effect of TIMP-1 (0.05–0.2 mg/Kg) in an experimental tail-bleeding model. In CHN, TIMP-1 was associated with admission-hematoma volume and MMP-7 was elevated in patients with deep when compared to lobar hematoma. In VdH, admission-hematoma volume was associated with TIMP-1 and MMP-7. When data from both hospitals were combined, we observed that an increase in 1 ng/ml in TIMP-1 was associated with an increase of 0.14 ml in haemorrhage (combined β = 0.14, 95% CI = 0.08–0.21). Likewise, mice receiving TIMP-1 (0.2 mg/Kg) showed a shorter bleeding time (p < 0.01). Therefore, the association of TIMP-1 with hematoma volume in two independent ICH cohorts suggests its potential as ICH biomarker. Moreover, increased TIMP-1 might not be sufficient to counterbalance MMPs upregulation indicating that TIMP-1 administration might be a beneficial strategy for ICH., This work was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III [PI15/01807, PI19/00065] and Federal Ministry of Education and Research (FEDER) funds; grants from the Spanish Society of Thrombosis and Haemostasis (SETH), Navarra Government (02/2015), Patrimonio Praga (Mexico) and Virto Group (Navarra, Spain); and a PhD scholarship from the Asociación de Amigos de la Universidad de Navarra (ADA).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

CM-352 efficacy in a mouse model of anticoagulant-associated intracranial hemorrhage

  • Navarro-Oviedo, Manuel
  • Marta-Enguita, Juan
  • Roncal Mancho, Carmen
  • Rodríguez, José Antonio
  • Zandio, Beatriz
  • Lecumberri, Ramón
  • Hermida, José
  • Oyarzabal, Julen
  • Pineda Lucena, Antonio
  • Páramo, José A.
  • Muñoz, Roberto
  • Orbe, Josune
Background Intracranial hemorrhage (ICH) is one of the major devastating complications of anticoagulation. Matrix metalloproteinase (MMP) inhibition has been proposed as a novel pharmacological approach for ICH treatment. Objectives We evaluated the effects of CM-352 (MMP-fibrinolysis inhibitor) in an experimental ICH model associated with oral anticoagulants as compared with clinically used prothrombin complex concentrate (PCC). Methods ICH was induced by collagenase injection into the striatum of wild type (C57BL/6J) anticoagulated mice (warfarin or rivaroxaban) and Mmp10 −/− mice. Hematoma volume and neurological deficits were measured 24 hours later by diaminobenzidine staining and different behavioral tests. Circulating plasminogen activator inhibitor-1 (PAI-1) activity and interleukin-6 (IL-6) were measured in plasma samples and local inflammation was assessed by neutrophil infiltration. Finally, fibrinolytic effects of MMP-10 and rivaroxaban were evaluated by thromboelastometry and thrombin-activatable fibrinolysis inhibitor (TAFI) activation assays. Results Only PCC reduced hemorrhage volume and improved functional outcome in warfarin-ICH, but both PCC and CM-352 treatments diminished hemorrhage volume (46%, p < 0.01 and 64%, p < 0.001, respectively) and ameliorated functional outcome in rivaroxaban-ICH. We further demonstrated that CM-352, but not PCC, decreased neutrophil infiltration in the hemorrhage area at 24 hours. The effect of CM-352 could be related to MMP-10 inhibition since Mmp10 −/− mice showed lower hemorrhage volume, better neurological score, reduced IL-6 levels and neutrophil infiltration, and increased PAI-1 after experimental ICH. Finally, we found that CM-352 reduced MMP-10 and rivaroxaban-related fibrinolytic effects in thromboelastometry and TAFI activation. Conclusion CM-352 treatment, by diminishing MMPs and rivaroxaban-associated fibrinolytic effects, might be a novel antihemorrhagic strategy for rivaroxaban-associated ICH., This work was supported by ISCIII (PI15/01807 and PI19/00065¿), co-funded by ERDF, ¿A way to make Europe¿, the Spanish Society of Thrombosis and Haemostasis (SETH), the Navarra Government (02/2015), and the Virto Group (Navarra, Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator

  • Roncal Mancho, Carmen
  • Martínez de Lizarrondo, Sara
  • Salicio, Agustina
  • Chevilley, Arnaud
  • Rodríguez, José Antonio
  • Rosell, Anna
  • Couraud, Pierre-Olivier
  • Weksler, Babette
  • Montaner, Joan
  • Vivien, Denis
  • Páramo, José A.
  • Orbe, Josune
Aims Early reperfusion with tissue-type plasminogen activator (tPA) is an effective therapeutic strategy to treat acute ischemic stroke, but only 1/3 of tPA-treated patients recover and are free from disability. tPA has also shown neurotoxicity in experimental models of cerebral ischemia. Considering that MMP-10 improves stroke injury, we have examined the therapeutic and protective effect of MMP10 and tPA/MMP10 as clot-dissolving and neuroprotective agent in an experimental model of ischemic stroke and studied in vitro the molecular pathways involved in MMP10-mediated effects. Methods and results Cerebral ischemia was induced by the local injection of thrombin into the middle cerebral artery followed by reperfusion with MMP10 (6.5 ¿g/kg) and tPA (10 mg/kg) alone or in combination with MMP10. Cell cultures were also performed to determine the effect of MMP10 and tPA/MMP10 on brain endothelial cells and neurons. tPA/MMP10 significantly reduced the infarct size in the ischemic stroke model compared with tPA alone (P < 0.05). In vitro, MMP10 reduced the tPA-promoted endothelial ionic permeability, preserved the expression of claudin-5 and decreased ERK1/2 activation. Moreover, combination of tPA/MMP10 prevented tPA-mediated neuronal excitotoxicity and calcium influx. These effects were reversed by blocking MMP10 activity with a monoclonal antibody. Conclusion These results show that MMP10, either alone or in combination with tPA, might represent a new strategy for thrombolysis in ischemic stroke, providing higher protection against cerebrovascular damage., Our work was supported by the Foundation for Applied Medical Research, University of Navarra (Pamplona, Spain); Ministerio de Economía y Competitividad (MINECO) and Federal Ministry of Education and Research (FEDER) funds [FIS PI15/01807]; MINECO [ERANET-Neuron, PRI-PIMNEU-2011-1334]; [RD12/0042/0009]; grants from Spanish Society of Thrombosis and Hemostasis [SETH]; and Navarra Government (02/2015).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage

  • Navarro-Oviedo, Manuel|||0000-0003-2095-5501
  • Muñoz-Arrondo, Roberto|||0000-0001-5518-7085
  • Zandio, Beatriz
  • Marta-Enguita, Juan|||0000-0003-1807-4297
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Rodríguez, Jose Antonio|||0000-0002-2094-264X
  • Roncal, Carmen|||0000-0003-0616-9600
  • Páramo, Jose A.|||0000-0003-1497-6242
  • Toledo, Estefania|||0000-0002-6263-4434
  • Montaner, Joan|||0000-0003-4845-2279
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Orbe, Josune|||0000-0001-6300-7670
Matrix metalloproteinases (MMPs) are proteolytic zinc-endopeptidases regulated by tissue Inhibitors of matrix metalloproteinases (TIMPs). We evaluated the potential of MMPs and TIMPs as clinical tools for Intracranial Haemorrhage (ICH). Spontaneous non-traumatic ICH patients were recruited from two hospitals: Complejo Hospitalario de Navarra (CHN = 29) and Vall d'Hebron (VdH = 76). Plasmatic levels of MMP-1, -2, -7, -9, -10 and TIMP-1 and their relationship with clinical, radiological and functional variables were evaluated. We further studied the effect of TIMP-1 (0.05-0.2 mg/Kg) in an experimental tail-bleeding model. In CHN, TIMP-1 was associated with admission-hematoma volume and MMP-7 was elevated in patients with deep when compared to lobar hematoma. In VdH, admission-hematoma volume was associated with TIMP-1 and MMP-7. When data from both hospitals were combined, we observed that an increase in 1 ng/ml in TIMP-1 was associated with an increase of 0.14 ml in haemorrhage (combined β = 0.14, 95% CI = 0.08-0.21). Likewise, mice receiving TIMP-1 (0.2 mg/Kg) showed a shorter bleeding time (p < 0.01). Therefore, the association of TIMP-1 with hematoma volume in two independent ICH cohorts suggests its potential as ICH biomarker. Moreover, increased TIMP-1 might not be sufficient to counterbalance MMPs upregulation indicating that TIMP-1 administration might be a beneficial strategy for ICH